November 2012 | Oncology & Biotech News

Adjunctive Ketamine Does Not Relieve Cancer Pain

December 05, 2012

Subcutaneous ketamine administered in conjunction with opioids and conventional adjuvant therapy does not lessen chronic uncontrolled cancer pain, according to the results of a phase III study. The regimen also produces a significant spike in toxicity.

Researchers Seek Optimal Dose of Cabozantinib in mCRPC

December 05, 2012

Single-agent cabozantinib has shown promising activity in early-stage trials involving heavily pretreated patients with metastatic castration-resistant prostate cancer. Researchers are now attempting to find the optimal dose of the drug in this patient population.

Addition of Motesanib to Chemotherapy Offers No Benefit for Patients With Non-Small Cell Lung Cancer

November 27, 2012

Motesanib combined with carboplatin/paclitaxel does not significantly improve OS versus carboplatin/ paclitaxel alone in patients with advanced nonsquamous non–small cell lung cancer, according to the results of the phase III MONET1 study.

Nab-Paclitaxel Extends PFS Versus Standard Chemotherapy in Patients With Metastatic Melanoma

November 26, 2012

A phase III trial that compared nab-paclitaxel (nab-P; Abraxane) with dacarbazine (DTIC) in patients with metastatic malignant melanoma (MMM) found that nab-P nearly doubled the median time to progression-free survival (PFS).

Biomarker May Predict Response to Bevacizumab in mCRC

November 26, 2012

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer (mCRC) treated with bevacizumab (Avastin), suggesting that patients who have the appropriate biomarker could experience a greater benefit when given the drug, whereas others who do not express the biomarker could be spared from receiving unnecessary therapy.

Patient and Physician Decision Practices Influence Chemotherapy Use in Older Patients With Breast Cancer

November 21, 2012

Older women with breast cancer who prefer less input from their physician when deciding on treatment are less likely to receive chemotherapy than women who prefer to rely on their physician to a greater degree, a recent study has found.